The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma

Mackenzie, Isla S.; Gurnell, Mark; Balan, Kottekkattu; Simpson, HL; Chatterjee, Krishna; Brown, M. J.

doi:10.1530/eje-07-0369

Cited by 43 publications

(21 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nonetheless, we found the combination of MRI and 123 I-MIBG to be sufficient in most cases. Although Timmers et al (2007a) recently reported the superiority of 18 F-fluorodeoxyglucose positron emission tomography ( 18 F-FDG PET) in the evaluation of metastatic paraganglioma, one might argue that in our cohort, because most of the paragangliomas were benign, the use of 18 F-fluorodopamine or 18 F-fluoro-dihydroxyphenylalanine ( 18 F-FDOPA) PET would be more appropriate after negative MIBG imaging (Pacak et al 2001, Hoegerle et al 2002, Hoegerle et al 2003, Mackenzie et al 2007). In our study, the sensitive and specific assays for O-methylated catecholamine metabolites (metanephrine and normetanephrine) were introduced for screening only in the last few years.…”

Section: B Havekes Et Al: Screening In Sdhd Patientsmentioning

confidence: 89%

Pheochromocytomas and extra-adrenal paragangliomas detected by screening in patients with SDHD-associated head-and-neck paragangliomas

Havekes

Klaauw²,

Weiss³

et al. 2009

Endocrine-Related Cancer

View full text Add to dashboard Cite

Patients with SDHD-associated head-and-neck paragangliomas (HNP) are at risk for developing pheochromocytomas for which screening has been advised. To assess clinical, biochemical, and radiological outcomes of screening in a large single-center cohort of SDHD-positive patients with HNP and to address the necessity for repetitive follow-up, we evaluated 93 patients with SDHDassociated HNP (p.Asp92Tyr, p.Leu139Pro). Screening consisted of measurement of 24 h urinary excretion of catecholamines and/or their metabolites in duplicate, which was repeated with intervals of 2 years if initial biochemical screening was negative. In patients, in whom urinary excretion was above the reference limit, imaging studies with 123 I-MIBG (metaiodobenzylguanidine) scintigraphy and magnetic resonance imaging (MRI) and/or computed tomography (CT) were performed. Pheochromocytomas and extra-adrenal paragangliomas were treated surgically after appropriate blockade. Median follow-up was 4.5 years (range 0.5-19.5 years). Twenty-eight out of the 93 patients were included in our study and underwent additional imaging for pheochromocytomas/extra-adrenal paragangliomas. In 11 out of the 28 patients intra-adrenal pheochromocytomas were found. Extra-adrenal paragangliomas were discovered in eight patients. These tumors were detected during initial screening in 63% of cases, whereas 37% were detected after repeated biochemical screening. One patient was diagnosed with a biochemically silent pheochromocytoma. The high prevalence of pheochromocytomas/extra-adrenal paragangliomas in patients with SDHD-associated HNP warrants regular screening for tumors in these patients. Paragangliomas that do not secrete catecholamines might be more prevalent than previously reported. Future studies will have to establish whether routine imaging studies should be included in the screening of SDHD mutation carriers, irrespective of biochemical screening.

show abstract

Section: B Havekes Et Al: Screening In Sdhd Patientsmentioning

confidence: 89%

Pheochromocytomas and extra-adrenal paragangliomas detected by screening in patients with SDHD-associated head-and-neck paragangliomas

Havekes

Klaauw²,

Weiss³

et al. 2009

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…Furthermore, MIBG may miss additional HNPs in hereditary syndromes. 18 F-FDOPA PET was found to be more sensitive than MIBG scintigraphy in the staging and restaging of paragangliomas (42,50,(54)(55)(56)(57)(58)(59). In some studies, 18 F-FDOPA PET significantly detected more lesions than CT/MRI.…”

Section: Extraadrenal Retroperitoneal Paragangliomasmentioning

confidence: 99%

Modern Nuclear Imaging for Paragangliomas: Beyond SPECT

et al. 2012

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to describe (1) the best nuclear imaging procedures to detect pheochromocytomas/paragangliomas according to the clinical situation (e.g., sporadic vs. hereditary; primary vs. metastatic; sympathetic vs. parasympathetic) and (2) the differences in the phenotypic information obtained by various PET tracers.Financial Disclosure: The authors of this article have indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNM designates each JNM continuing education article for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only credit commensurate with the extent of their participation in the activity.For CE credit, participants can access this activity through the SNM Web site (http://www.snm.org/ce_online) through February 2013.Paragangliomas are rare neuroendocrine tumors that may arise anywhere along the paraganglial system, with a high frequency of hereditary forms or multifocal disease. Most often, paragangliomas are benign and progress slowly, but metastases may occur in about 10% of patients. In this respect, nuclear imaging in combination with anatomic imaging may be required to fully delineate the extent of the disease. PET has been increasingly used in imaging paraganglioma, paralleled by great efforts toward the development of new tracers. Recent data indicate that the choice of PET tracers should be tailored to tumor localization and to the patient's genetic status. This article provides insight into the many PET radiotracers that are currently available and others that are still only under research and guides clinicians toward appropriate use in relation to genetic carrier status. In addition, this article provides nuclear medicine physicians with the background knowledge required for understanding relationships between imaging phenotypes and molecular genetics.

show abstract

“…From these 21 articles potentially eligible for inclusion, after reviewing the full-text article, six articles were excluded as case reports or small case series [12][13][14][15][16][17], one due to data overlap [18], and three due to insufficient data to calculate sensitivity or specificity of 18 F-DOPA PET [19][20][21].…”

Section: Literature Searchmentioning

confidence: 99%

Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis

Treglia

Cocciolillo

Waure

et al. 2012

Eur J Nucl Med Mol Imaging

101

View full text Add to dashboard Cite

show abstract

The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma

Cited by 43 publications

References 8 publications

Pheochromocytomas and extra-adrenal paragangliomas detected by screening in patients with SDHD-associated head-and-neck paragangliomas

Pheochromocytomas and extra-adrenal paragangliomas detected by screening in patients with SDHD-associated head-and-neck paragangliomas

Modern Nuclear Imaging for Paragangliomas: Beyond SPECT

Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis

Contact Info

Product

Resources

About